ARDS Covid-19 Antibody Cocktail | Massive Bullish Divergence

NASDAQ:ARDS   Aridis Pharmaceuticals Inc
The chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon!

Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."

Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."

ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.

It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.

Market Cap 27.124Mil
52 Week Range 1.89 - 8.47

I think this might be our 10X stock for 2022.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.